Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2000
08/23/2000EP1028726A1 Method and composition for treatment of sexual dysfunction
08/23/2000EP1028725A1 Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear
08/23/2000EP1028716A1 Method for treating and preventing heart failure and ventricular dilatation
08/23/2000EP1028715A1 Dosage composition for nasal delivery and method of use of the same
08/23/2000EP1028707A1 Sustained release ophthalmic compositions containing water soluble medicaments
08/23/2000EP1028705A1 Uses of d-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells
08/23/2000EP1028690A2 Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
08/23/2000CN1264308A Medicinal compositions for treating immunodeficinecy diseases
08/23/2000CN1264307A Method of enhancing function of upper gastrointestinal tract
08/23/2000CN1264303A Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
08/23/2000CN1264302A Treatment of diabetes with thiazolidinedione and sulphonylurea
08/22/2000US6107473 Kringle-related clone HTHBZ47
08/22/2000US6107334 Dietary control of arachidonic acid metabolism
08/22/2000US6107328 Use of 5HT1B receptor antagonist for the treatment of vascular disease
08/22/2000US6107327 Therapeutic treatment for HIV infection
08/22/2000US6107323 Preventing or treating angiotensin diseases by administering an antagonist and compound which increases insulin sensitivity
08/22/2000US6107090 Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
08/22/2000US6107073 Kinase capable of site-specific phosphorylation of IκBα
08/22/2000US6107071 Polynucleotide or complementary sequence which codes for a specific staphylococcus aureus amino acid sequence; for diagnosis of bacterial infections; screening of bactericides, bacteriostats, and antibiotics
08/22/2000US6107041 Detecting modulators of inhibitor of apoptosis; incubating cell that expresses inhibitor of apoptosis with modulator, monitor the expression of inhibitor of apoptosis, increase in apoptosis is indicator of the presence of a modulator
08/22/2000US6106858 Loading active materials of liposomes by dissolving
08/22/2000US6106819 Administering anesthetic and antiinflammatory agent to eye
08/22/2000US6106805 Diagnostic composition containing an LH-RH antagonist for hysteroscopy
08/17/2000WO2000047734A1 Inhibiting formation of atherosclerotic lesions
08/17/2000WO2000047725A1 Nitroreductase enzymes
08/17/2000WO2000047723A2 Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same
08/17/2000WO2000047625A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
08/17/2000WO2000047624A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods
08/17/2000WO2000047620A1 Cytokine-binding domain
08/17/2000WO2000047619A1 Therapeutics and diagnostics based on an il-1b mutation
08/17/2000WO2000047618A2 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
08/17/2000WO2000047611A2 Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
08/17/2000WO2000047610A2 Method for altering undesirable immune responses to polypeptides
08/17/2000WO2000047591A1 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
08/17/2000WO2000047558A1 Amide compounds and medicinal use thereof
08/17/2000WO2000047284A2 Novel use of orexin receptor antagonists
08/17/2000WO2000047231A2 Novel antisense inhibition of rad51
08/17/2000WO2000047230A1 Anticancer agent potentiators
08/17/2000WO2000047229A2 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
08/17/2000WO2000047228A1 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
08/17/2000WO2000047219A2 Methods and reagents for treating glucose metabolic disorders
08/17/2000WO2000047216A1 Immunogenic compositions for use as vaccines
08/17/2000WO2000047214A1 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
08/17/2000WO2000047213A1 Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same
08/17/2000WO2000047207A1 LACTAM INHIBITORS OF FXa AND METHOD
08/17/2000WO2000047206A1 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
08/17/2000WO2000047205A1 Tyrosine kinase inhibitors and methods of using the same
08/17/2000WO2000047198A2 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
08/17/2000WO2000047197A2 Alkylating agents for treatment of cellular proliferation
08/17/2000WO2000047196A2 Use of statins for treating viral infections
08/17/2000WO2000047195A1 Stimulating neutrophil function to treat inflammatory bowel disease
08/17/2000WO2000047188A1 Oxadiazole compounds and compositions for delivering active agents
08/17/2000WO2000047130A1 Injectable collagen-based system for delivery of cells or therapeutic agents
08/17/2000WO2000047104A2 Antagonists of hmg1 for treating inflammatory conditions
08/17/2000WO2000031273A3 Process for oxidising terpenes
08/17/2000WO2000030675A3 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
08/17/2000WO2000030590A3 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
08/17/2000WO2000024766A3 New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
08/17/2000WO2000020602A3 Delta 6 and delta 12 desaturases and modified fatty acid biosynthesis and products produced therefrom
08/17/2000WO2000018912A3 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
08/17/2000WO2000012076A9 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
08/17/2000WO2000009109A3 Pipecolic acid derivatives for vision and memory disorders
08/17/2000CA2367575A1 Stimulating neutrophil function to treat inflammatory bowel disease
08/17/2000CA2363088A1 Methods for treating viral infections
08/17/2000CA2362883A1 Alkylating agents for treatment of cellular proliferation
08/17/2000CA2362662A1 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
08/17/2000CA2362592A1 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
08/17/2000CA2362523A1 Nitroreductase enzymes
08/17/2000CA2362426A1 Anticancer drug enhancer
08/17/2000CA2362373A1 Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
08/17/2000CA2362368A1 Method for altering undesirable immune responses to polypeptides
08/17/2000CA2362295A1 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
08/17/2000CA2362109A1 Novel antisense inhibition of rad51
08/17/2000CA2361569A1 Injectable collagen-based system for delivery of cells or therapeutic agents
08/17/2000CA2361335A1 Inhibiting formation of atherosclerotic lesions
08/17/2000CA2360324A1 Peptide yy (pyy) for inducing glucose responsiveness in pancreatic islets
08/17/2000CA2360319A1 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
08/17/2000CA2360305A1 Lactam inhibitors of fxa and method
08/17/2000CA2360292A1 Immunogenic compositions for use as vaccines
08/17/2000CA2359926A1 Antagonists of hmg1 for treating inflammatory conditions
08/17/2000CA2359785A1 .beta.-secretase enzyme compositions and methods
08/16/2000EP1028137A2 Polymeric matrices and their uses in pharmaceutical compositions
08/16/2000EP1027892A2 Azithromycin combination for emesis control in dogs
08/16/2000EP1027890A2 Homer a new target of treating psychiatric disorders
08/16/2000EP1027887A2 Matrix controlled release device
08/16/2000EP1027834A1 Food composition comprising L-arginine
08/16/2000EP1027443A2 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
08/16/2000EP1027438A2 Novel cytokine receptors
08/16/2000EP1027437A1 Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
08/16/2000EP1027431A2 April- a novel protein with growth effects
08/16/2000EP1027429A1 Jnk3 modulators and methods of use
08/16/2000EP1027370A2 A method for mapping the active sites bound by enzymes that covalently modify substrate molecules
08/16/2000EP1027098A1 Electrically activated substance and method for making the same
08/16/2000EP1027071A2 Encapsulated immunomodulators useful as vaccine adjuvants
08/16/2000EP1027067A1 Use of substances having oxytocin activity for preparation of medicaments for the treatment of affective pain syndromes
08/16/2000EP1027059A2 Enhancement of morphogen activity
08/16/2000EP1027057A1 Treatment of female sexual dysfunction
08/16/2000EP1027054A1 Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
08/16/2000EP1027053A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
08/16/2000EP1027052A1 Novel combination
1 ... 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 ... 1151